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Background: Major bleeding increases risk for adverse events following PCI. The
frequency and impact of less severe, or nuisance bleeding, on adverse events after PCI
remains unknown.
Methods: PARIS was a multinational, prospective registry of patients prescribed DAPT
following PCI for any indication from 2009 to 2010 (n¼5,018). Nuisance bleeding was
deﬁned as Bleeding Academic Research Consortium (BARC) type 1. Minor or major
bleeding included BARC  2. Patients were categorized by bleeding severity. Associa-
tions between bleeding and adverse events were examined using Cox regression with
bleeding entered as a time-update covariate. All events were independently adjudicated.
Results: Over 2 years, the cumulative occurrence of nuisance bleeding was 18.0%
(n¼835). Compared to those with more severe bleeding (n¼ 401, 8.3%), patients with
nuisance bleeding were younger, less often female and less likely to receive triple
therapy on discharge. Two-year rates of ischemic adverse events (def/prob stent
thrombosis, myocardial infarction or cardiac death) were 5.6%, 4.9% and 20.1%
among those with none, nuisance, and minor/major bleeding, respectively. Results
were unchanged after multivariable adjustment (Table).
MI-myocardial infarction; Models adjusted for age, gender, region, acute coronary
syndrome, stent type, warfarin use. Adjusted Hazard ratios calculated from Cox
Models with bleeding entered as a time-updated covariate.Table. Hazard Ratios (95% Conﬁdence Intervals) for Ischemic Events
Associated with Bleeding Severity
Spontaneous MI Cardiac Death MACE
No Bleed 1.0 (ref) 1.0 (ref) 1.0 (ref)
Nuisance Bleed 1.19 (0.65-2.17) 0.63 (0.25-1.55) 0.91 (0.54-1.51)
Minor/Major Bleed 2.70 (1.68-4.32) 4.28 (2.82-6.47) 2.82 (2.0-3.98)
MI-myocardial infarction; Models adjusted for age, gender, region, acute coronary syndrome,
stent type, warfarin use. Adjusted Hazard ratios calculated from Cox Models with bleeding
entered as a time-updated covariate.Conclusions: Although common, nuisance bleeding is not associated with an
increased risk for ischemic adverse events following PCI.
TCT-491
High incidence of stent thrombosis with new P2Y12 inhibitors after percutaneous
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Background: Acute coronary syndromes (ACS) remain the leading cause of out-of-
hospital cardiac arrest (OHCA). Current guidelines plead for early coronary angiog-
raphy and ad-hoc primary percutaneous coronary intervention (PCI). But after cardiac
arrest, shock, hypothermia and modiﬁcation in antiplatelet pharmacokinetic may
promote stent thrombosis (ST). The aim of this study was to evaluate incidence of ST
in survivors of OHCA successfully revascularized with stent implantation.
Methods: We conducted a retrospective observational analysis of all OHCA survivors
with successful PCI between 2011 and 2013. All patients were treated with mild
therapeutic hypothermia for 24h, and dual antiplatelet therapy according to current
guidelines. Clinical, angiographic and biological data were collected. Deﬁnite and
probable ST were reported according to the Academic Research Consortium deﬁnition.
Results: A total of 101 consecutive patients have been included in the present anal-
ysis. Mean age was 61.3 years. 75% of patients had initial ventricular ﬁbrillation.
Mean no ﬂow and low ﬂow were 4.0 +/- 4.3 min and 18.2+/-11.4 min, respectively.
All patients received aspirin before PCI. P2Y12 inhibitors were initiated after stent
implantation and include clopidogrel (48%), prasugrel (22%) or ticagrelor (30%). In
addition, 31% also received GpIIbIIIa inhibitors. The initial TIMI ﬂow was 0 or 1 in
53% of patients. Mean post-procedural left ventricular ejection fraction was 39.6+/-
12.4 %. Global survival rate at discharge was 45%. We identiﬁed 11 cases (10.9%) of
deﬁnite or probable ST (acute, n¼4 and subacute n¼7) with median delay to PCI of 2
days. Stent thrombosis occurred with clopidogrel (n¼2), prasugrel (n¼4) and tica-
grelor (n¼5). Mortality was higher in patients with ST (82% vs 52%; p¼0.06). We
reported more ST with new P2Y12 inhibitors compared to clopidogrel (17 % vs 4 %;
respectively, p¼0.05). Moreover no beneﬁt was observed with the use of pre-treat-
ment with aspirin (p¼0.94) or heparin (p¼0.75).JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/PhaConclusions: IncidenceofST inOHCAsurvivors is highand associatedwith poor clinical
outcome. Optimal antithrombotic therapy in this critical state remains to be determined.
TCT-492
Stent Thrombosis With Ticagrelor Versus Clopidogrel After Percutaneous
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Background: Dual antiplatelet therapy, aspirin in combination with a P2Y12
antagonist, has been shown to reduce occurrence of ischemic events after coronary
stent implantation in randomized clinical trials. We compared 1-year risk of stent
thrombosis among patients with acute coronary syndromes (ACS) having either pri-
mary percutaneous coronary intervention (PCI) due to ST-segment elevation
myocardial infarction (STEMI) or sub-acute PCI due to non-STEMI or unstable
angina pectoris and dual antiplatelet therapy with either ticagrelor or clopidogrel for
12 months.
Methods: From June 2010 to June 2012 all ACS patients treated with PCI at Odense
University Hospital were identiﬁed from the Western Denmark Heart Registry. From
June 2010 to June 2011 the standard dual antiplatelet therapy was aspirin and clo-
pidogrel (600-mg loading dose, 75 mg daily thereafter): “clopidogrel group” and from
June 2011 to June 2012 the standard dual antiplatelet therapy was changed to aspirin
and ticagrelor (180-mg loading dose, 90 mg twice daily thereafter): “ticagrelor group”.
We assessed the 1-year risk of deﬁnite stent thrombosis after PCI with stent im-
plantation including risk of acute, subacute and late deﬁnite stent thrombosis.
Results: The study cohort consisted of 2,335 patients withACS, ofwhom1,134 patients
were in the “ticagrelor group” and 1,201 patients were in the “clopidogrel group”. The 1-
year risk rate of deﬁnite stent thrombosis was reduced signiﬁcantly in the “ticagrelor
group” n¼5 (0.5%) compared to the “clopidogrel group” n¼17 (1.4%) [hazard ratio
(HR)¼0.31 95% conﬁdence interval (CI) 0.11-0.84]. Ticagrelor reduced especially the
rate of early (within 30 days) deﬁnite stent thrombosis compared with clopidogrel: n¼4
(0.4%) versus n¼15 (1.2%); [HR¼ 0.28 95% CI 0.09-0.85] with a numerically lower
number of acute (n¼1 (0.1%) vs. n¼5 (0.4%), p¼0.219) and subacute (n¼3 (0.3%) vs.
n¼10 (0.8%), p¼0.093) whereas risk of late deﬁnite stent thrombosis did not differ
between ticagrelor n¼1 (0.1%) and clopidogrel n¼2 (0.2%) treated patients.
Conclusions: In a real world setting, treatment with ticagrelor as compared with
clopidogrel in ACS patients signiﬁcantly reduced the risk of deﬁnite stent thrombosis.
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Background: Few studies have examined the safety and effectiveness of prasugrel vs.
clopidogrel in the context of bivalirudin vs. heparin use.
Methods: We evaluated 10,493 STEMI and NSTEMI patients treated with percutaneous
coronary intervention (PCI) at 230 hospitals in the TRANSLATE-ACS observational
study from 4/2010–10/2012. Patients were stratiﬁed based on anticoagulant (bivalirudin
vs. heparinGPI) and antiplatelet (prasugrel vs. clopidogrel) treatment. Outcomes of 30-
day GUSTO-deﬁned bleeding and MACE (death, MI, stroke, or unplanned revasculari-
zation) were compared between groups propensity matched for treatment.
Results: In the overall study population, there were signiﬁcant differences in patient
characteristics, such as age, sex, prior MI, prior CABG, diabetes, STEMI presentation,
and coronary disease burden, between observed treatment groups. After 1:1 propensity
matching, these characteristics were well-balanced between each set of comparison
groups (Cramers F < 0.05). In propensity matched comparisons, the risk of bleeding
was lower among bivalirudin-treated patients compared with those who received
heparinGPI (Table). The 30-day risk of GUSTO bleeding was not signiﬁcantly
different between prasugrel and clopidogrel among bivalirudin-treated patients, nor
among heparin-treated patients. The 30-day risk of MACE was also similar between
prasugrel and clopidogrel regardless of bivalirudin or heparin use.
Conclusions: In routine practice, the patterns of use are quite different in patients treated
with these antiplatelet and anticoagulant therapies. However, 30-day outcomes were not
signiﬁcantly different between prasugrel and clopidogrel, regardless of anticoagulant
choice. Bleeding risk was lower with bivalirudin regardless of antiplatelet choice.rmacotherapy - Aspirin, Thienopyridines and other Platelet Inhibitors B145
Antiplatelet Effects of Clopidogrel and Aspirin
Day 1 Day 30 Day 180 p-
value
Clopidogrel
effect
VerifyNow PRU 169 (92, 240) 183 (122, 252) 194 (125, 245) 0.047
- PRU >208 36.4% 40.9% 42.2% 0.40
RPA ADP 5mM 11 (4, 22) 17 (8, 29) 15 (6, 31) 0.003
RPA ADP 20mM 24 (10, 43) 36 (22, 49) 32 (17, 49) 0.007
Aspirin effect VerifyNow ARU 393 (384, 408) 394 (384, 409) 395 (380, 411) 0.55
RPA AA 500 mg/
L
4 (2, 7) 6 (3, 8) 5 (4, 8) 0.18
Results shown as median (interquartile range); p-values by Friedman test.
Analysis Population
and Events
Rates in Propensity
Matched Groups*
Hazard Ratio (95%
Conﬁdence Interval)*
Overall Analysis
Population
Bivalirudin Heparin±GPI
30-day GUSTO
bleeding
3.0% 4.1% 0.72 (0.57-0.90)
30-day MACE 7.6% 8.2% 0.91 (0.78-1.06)
Bivalirudin Group Prasugrel Clopidogrel
30-day GUSTO
bleeding
2.7% 2.5% 1.07 (0.64-1.77)
30-day MACE 7.5% 6.7% 1.09 (0.80-1.48)
Heparin±GPI Group Prasugrel Clopidogrel
30-day GUSTO
bleeding
4.0% 4.3% 0.90 (0.63-1.30)
30-day MACE 5.4% 6.8% 0.85 (0.63-1.15)
*Unadjusted event rates and hazard ratios compare each outcome between treatment groups
after 1:1 propensity matching within the described analysis population.
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VerifyNow in DIabetes high-on-treatment platelet reactivity: a
pharmacodynamic study on switching from clopidogrel to prasugrel
(VERDI study)
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Background: Diabetic patients with acute coronary syndrome (ACS) undergoing
percutaneous coronary intervention (PCI) frequently exhibit high platelet reactivity
(HPR) while on clopidogrel. We aimed to test the hypothesis that in diabetic patients
with ACS undergoing PCI exhibiting HPR after standard treatment with clopidogrel, a
loading dose of 60 mg of prasugrel is superior to the standard treatment with clopi-
dogrel for the achievement of optimal P2Y12 inhibition within the ﬁrst 24-36 hours
post-PCI.
Methods: The VERDI was a prospective, randomized, single-center, single-blind,
parallel design study (NCT01684813). Consecutive diabetic patients with ACS un-
dergoing PCI and loaded with clopidogrel were considered for platelet reactivity (PR)
assessment immediately before PCI with the VerifyNow assay (Accumetrics Inc, San
Diego, CA), measured in P2Y12 reaction units (PRU). Out of 63 screened patients, 50
(79.3%) patients were found with HPR (deﬁned as PRU 208) and were randomized
to receive a loading dose of 60 mg prasugrel vs the standard dose of clopidogrel.
Platelet function was assessed again 24h post-PCI.
Results: Greater platelet inhibition was achieved by prasugrel compared with clopi-
dogrel at 24h post-PCI [38 (9-72) vs 285 (240-337), respectively; median (inter-
quartile range); p < 0.001]. The primary end point of non-HPR rate (PRU < 208) at
24h post-PCI was higher in the prasugrel group, twenty-ﬁve patients (100%) in the
prasugrel group achieved optimal antiaggregation versus 4 patients (16%) in the
clopidogrel group; p < 0.001. No signiﬁcant acute bleeding was documented in either
group.
Conclusions: Among type 2 diabetic patients with ACS and HPR undergoing PCI
with stent, switching from clopidogrel to prasugrel was superior to standard treatment
with clopidogrel for the achievement of optimal antiaggregation within the ﬁrst 24h
post-PCI.
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Impact of platelet reactivity on clopidogrel after PCI with 2nd generation DES on
late lumen loss
Naoei Isomura1, Seitarou Ebara2, Toshitaka Okabe2, Kennosuke Yamashita3,
Myong-Hwa Yamamoto2, Koichi Hoshimoto2, Shigeo Saito4, kisaki amemiya5,
Tadayuki Yakushiji2, Hiroshi Araki2, Masahiko Ochiai6
1Showa University Northern Yokohama Hospital, Yokohama, Kanagawa, 2Showa
Univesity Northern Yokohama Hospital, Yokohama, Kanagawa, 3Showa Univesity
Northern Yokohama Hospital, Yokohama, Japan, 4Cardiovascular Research
Foundation, New York, NY, 5Kokura Memorial Hospital, Kitakyushu, Fukuoka,
6Showa Universitty Northern Yokohama Hospital, Kanagawa, Japan
Background: Previous studies had reported that high platelet reactivity (HPR) is
associated with recurrent ischemic events after PCI. However, 1st generation drug-
eluting stents (DES) were mainly used in those studies. We measured platelet reac-
tivity after clopidogrel loading, late lumen loss by quantitative coronary angiographic
analysis (QCA) and assessed mid-term clinical outcomes in patients who underwent
PCI with 2nd generation DES.
Methods: Platelet reactive units (PRU) was measured by VerifyNow P2Y12 assays in
396 patients underwent PCI with Everolimus- or Biolimus-eluting stents between
August 2010 and May 2013. All patients received 300mg clopidogrel loadingB146 JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstraimmediately after PCI, 368 patients were followed by a maintenance dose of clopi-
dogrel (75-50mg/d) and aspirin (100mg/d). Blood samples were obtained 12 to 24
hours after PCI (initial phase) and 2-4 weeks later (chronic phase). HPR on clopidgrel
was deﬁned as 240 or more in PRU. We assessed major adverse cardiovascular event
(MACE) including the composite of death, nonfatal MI, stent thrombosis, stroke, and
target lesion revascularization (TLR), and bleeding events, QCA was evaluated at
baseline and 1-year follow-up.
Results: The value of PRU and rate of HPR on the chronic phase were signiﬁcantly
lower than in the initial phase (24981 vs. 21483; p< 0.001, 58% vs. 42%; p<
0.001). In the chronic phase, HPR group had more female and older patients than non-
HPR group. There were no signiﬁcant differences in MACE and bleeding events
between two groups (HPR 7.7% vs. non-HPR 7.5%; p¼NS). According to QCA, late
lumen loss was signiﬁcantly larger in HPR group compared to non-HPR group
(0.290.40mm vs. 0.170.37mm; p¼0.01). Multiple logistic regression analysis
indicated that HPR was the only independent predictor for late lumen loss of 0.3mm
and over (p¼0.015).
Conclusions: There was no signiﬁcant impact of platelet reactivity on clopidogrel on
clinical outcomes after PCI with 2nd generation DES. However, adequate inhibition of
platelet reactivity reduced late lumen loss.
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Background: Clinical studies have demonstrated an association between high on-
treatment platelet reactivity and ischemic events after coronary stent placement,
suggesting that platelet function testing may be used to guide antiplatelet therapy.
However, periprocedural platelet activation may falsely increase the proportion of
patients with high on-treatment platelet reactivity. We therefore investigated the
temporal variability in response to clopidogrel and aspirin for up to 6 months after
elective coronary placement of drug-eluting stents.
Methods:We determined platelet reactivity in whole blood (VerifyNow P2Y12 and
Aspirin assays) and in platelet rich plasma (light transmission aggregometry - LTA)
obtained from 121 unselected patients on day 1 after PCI following loading with
aspirin (300 mg), clopidogrel (600mg), and administration of the ﬁrst mainte-
nance dose of clopidogrel 75mg, followed by measurements on day 30 and day
180 after PCI on chronic treatment (clopidogrel 75mg qd, ASA 100mg qd). Re-
sidual platelet aggregation (RPA) was determined by LTA using adenosine
diphosphate (ADP; 5 and 20mM) and arachidonic acid (AA; 500 mg/L). P2Y12
Reaction Units (PRU) and Aspirin Reaction Units (ARU) were assessed using
VerifyNow assays.
Results: As seen in the Table, platelet inhibition in response to aspirin was consistent
from day 1 to 180. The platelet response to clopidogrel decreased slightly over time.
However, deﬁning clopidogrel hyporesponsiveness as a PRU >208, the percentages
of hyporesponsive patients were 36.4%, 40.9% and 42.2% on day 1, 30 and 180
respectively (p¼0.40).Conclusions: Serial platelet function testing measured 1 day after aspirin and clopi-
dogrel loading and PCI reliably reﬂects the response to antiplatelet treatment for at
least 6 months.cts/Pharmacotherapy - Aspirin, Thienopyridines and other Platelet Inhibitors
